McKesson stock in focus after higher fiscal 2027 EPS outlook

Published on 11/12/2026 at 13:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock enters the second half with stronger earnings expectations. Revenue and adjusted profit both rose in the fiscal second quarter.

McKesson raises fiscal outlook

Fiscal second-quarter revenue increased 8% to 111.0 billion US dollars.
Adjusted diluted earnings per share rose 18% year over year to 11.68 US dollars.
Management lifted fiscal 2027 adjusted earnings guidance to 45.60 to 46.40 US dollars per diluted share.

McKesson, US58155Q1031, Illustration mit AI erstellt.

McKesson reported stronger fiscal 2027 second-quarter results on November 4 and raised its full-year adjusted earnings outlook. The healthcare distributor said consolidated revenue rose 8% year over year to 111.0 billion US dollars for the quarter ended September 30, according to its earnings release.

Quarterly growth supports higher guidance

Adjusted diluted earnings per share increased 18% from a year earlier to 11.68 US dollars. GAAP diluted earnings per share rose to 10.44 US dollars from 8.92 US dollars, while McKesson generated 3.1 billion US dollars in operating cash flow and 2.9 billion US dollars in free cash flow.

Management attributed the operating progress to growth in North American Pharmaceutical, Oncology and Multispecialty, and Prescription Technology Solutions. Higher prescription volumes and specialty-product distribution supported the quarter, although lower contributions from branded pharmaceuticals partly offset the gains.

McKesson raised its fiscal 2027 adjusted earnings per diluted share guidance to a range of 45.60 to 46.40 US dollars, up from the previous range of 44.20 to 45.00 US dollars. The new range implies adjusted earnings growth of 17% to 19% compared with the prior year.

Second-half execution remains central

The company expects fiscal 2027 revenue growth of 6% to 10% and adjusted operating profit growth of 12% to 16%. Management said the outlook reflects confidence in the strength of the business and its ability to execute consistently through the second half.

The updated earnings outlook includes effects from the Norway divestiture and net gains within The US Oncology Network in fiscal 2026. Excluding those items, management indicated adjusted earnings growth of 19% to 21%, above its long-term target range of 13% to 16%.

McKesson stock traded at 982.40 euros on Lang & Schwarz at 13:38 CET on Thursday, November 12, 2026.